NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD
39.57
+1 (+2.59%)
The current stock price of QGEN is 39.57 USD. In the past month the price decreased by -13.66%. In the past year, price decreased by -9.7%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
DHR | DANAHER CORP | 28.07 | 151.18B | ||
A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
WAT | WATERS CORP | 31.58 | 22.26B | ||
ICLR | ICON PLC | 14.39 | 16.63B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
RVTY | REVVITY INC | 23.23 | 13.85B | ||
AVTR | AVANTOR INC | 17.3 | 11.78B | ||
TEM | TEMPUS AI INC | N/A | 10.72B |
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,967 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG 5912 NL
CEO: Thierry Bernard
Employees: 5900
Company Website: https://www.qiagen.com/
Investor Relations: https://corporate.qiagen.com/investor-relations/overview
Phone: 31773556600
The current stock price of QGEN is 39.57 USD. The price increased by 2.59% in the last trading session.
The exchange symbol of QIAGEN N.V. is QGEN and it is listed on the New York Stock Exchange, Inc. exchange.
QGEN stock is listed on the New York Stock Exchange, Inc. exchange.
22 analysts have analysed QGEN and the average price target is 51.88 USD. This implies a price increase of 31.1% is expected in the next year compared to the current price of 39.57. Check the QIAGEN N.V. stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QIAGEN N.V. (QGEN) has a market capitalization of 8.55B USD. This makes QGEN a Mid Cap stock.
QIAGEN N.V. (QGEN) currently has 5900 employees.
QIAGEN N.V. (QGEN) has a support level at 39.56 and a resistance level at 39.58. Check the full technical report for a detailed analysis of QGEN support and resistance levels.
The Revenue of QIAGEN N.V. (QGEN) is expected to grow by 5.1% in the next year. Check the estimates tab for more information on the QGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QGEN does not pay a dividend.
QIAGEN N.V. (QGEN) will report earnings on 2025-04-30, after the market close.
The PE ratio for QIAGEN N.V. (QGEN) is 18.07. This is based on the reported non-GAAP earnings per share of 2.19 and the current share price of 39.57 USD. Check the full fundamental report for a full analysis of the valuation metrics for QGEN.
The outstanding short interest for QIAGEN N.V. (QGEN) is 1.21% of its float. Check the ownership tab for more information on the QGEN short interest.
ChartMill assigns a fundamental rating of 6 / 10 to QGEN. QGEN has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS increased by 3.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.23% | ||
ROA | 1.47% | ||
ROE | 2.34% | ||
Debt/Equity | 0.38 |
ChartMill assigns a Buy % Consensus number of 78% to QGEN. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 7.19% and a revenue growth 5.1% for QGEN